COVID-19 and Convalescent Plasma

The use of convalescent plasma (CP) collected from previously infected individuals to passively transfer antibodies so as to guard or treat humans dates back almost 100 years. Results from small case series during the prior MERS and SARS coronavirus outbreaks suggested that CP is safe and should confer clinical benefits, including faster viral clearance, particularly when administered early within the disease course1. The overwhelming majority of patients who get over COVID-19 illness develop circulating antibodies to varied SARS-CoV-2 proteins 2-3 weeks following infection, which are detectable by ELISA or other quantitative assays and sometimes correlate with the presence of neutralizing antibodies.

Donations can occur as frequently as weekly for several months before antibody titers begin decreasing. Allowed donation frequency varies between blood centers. Listed below are some sites for referral of potential donors.

  • AABB
  • FDA donate COVID-19 plasma
  • Hyper immune globulin
  • National COVID-19 Convalescent plasma project

Related Conference of COVID-19 and Convalescent Plasma

October 17-18, 2022

21st International Conference on Structural Biology

Barcelona, Spain
November 15-16, 2022

3rd Experts Meeting on Plant, Cellular and Molecular Biology

Budapest, Hungary
November 21-22, 2022

4th Annual summit on Cell Signaling and Cancer Therapy

Montreal, Canada
May 03-04, 2023

16th World Congress on Stem Cell Research

Paris, France
May 03-04, 2023

Global Conference on Cell and Gene Therapy

Paris, France

COVID-19 and Convalescent Plasma Conference Speakers

Recommended Sessions

Related Journals

Are you interested in